<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6889349/results/search/disease/results.xml">
  <result pre="Commercially available antiviral drugs, when used in the treatment of" exact="viral" post="infections, do not always result in success. This is"/>
  <result pre="H5N3, H1N1 and H3N2) and paramyxoviruses (Sendai Virus and Newcastle" exact="Disease" post="Virus). The antiviral activity of these selected extracts was"/>
  <result pre="activities when tested using influenza viruses, Sendai Virus, and Newcastle" exact="Disease" post="Virus. These activities were comparable to those shown by"/>
  <result pre="were isolated from extremophilic microorganisms. Research highlights that drug-resistance in" exact="type A" post="influenza virus is of high concern since it led"/>
  <result pre="the virus can result in a new outbreak due to" exact="infections" post="by the influenza virus [4]. Other viruses that serve"/>
  <result pre="to the animal populations come from the family Paramyxoviridae, specifically" exact="Newcastle disease" post="virus and Sendai virus [6]. For example, the Newcastle"/>
  <result pre="the animal populations come from the family Paramyxoviridae, specifically Newcastle" exact="disease" post="virus and Sendai virus [6]. For example, the Newcastle"/>
  <result pre="Newcastle disease virus and Sendai virus [6]. For example, the" exact="Newcastle disease" post="virus is distributed worldwide and has the potential to"/>
  <result pre="disease virus and Sendai virus [6]. For example, the Newcastle" exact="disease" post="virus is distributed worldwide and has the potential to"/>
  <result pre="Sendai virus, also known as murine and human parainfluenza virus" exact="type 1," post="severely infects the respiratory system of rodents and only"/>
  <result pre="murine and human parainfluenza virus type 1, severely infects the" exact="respiratory" post="system of rodents and only mildly in humans, respectively"/>
  <result pre="the development of new compounds for advancing drug-based therapies against" exact="viral" post="infections such as influenza and paramyxoviruses. Known sources for"/>
  <result pre="development of new compounds for advancing drug-based therapies against viral" exact="infections" post="such as influenza and paramyxoviruses. Known sources for new"/>
  <result pre="metabolites with antiviral activities against several pathogenic viruses which include" exact="Western equine encephalitis" post="virus, HIV-1, Zika virus, acyclovir-resistant herpes simplex virus type"/>
  <result pre="antiviral activities against several pathogenic viruses which include Western equine" exact="encephalitis" post="virus, HIV-1, Zika virus, acyclovir-resistant herpes simplex virus type"/>
  <result pre="which include Western equine encephalitis virus, HIV-1, Zika virus, acyclovir-resistant" exact="herpes" post="simplex virus type 1 as well as influenza A"/>
  <result pre="equine encephalitis virus, HIV-1, Zika virus, acyclovir-resistant herpes simplex virus" exact="type 1" post="as well as influenza A and B viruses [11–14]."/>
  <result pre="A and B viruses [11–14]. The genomic RNA (3′-5) of" exact="Newcastle disease" post="virus that is 15,186 nucleotides long encodes the nucleocapsid,"/>
  <result pre="and B viruses [11–14]. The genomic RNA (3′-5) of Newcastle" exact="disease" post="virus that is 15,186 nucleotides long encodes the nucleocapsid,"/>
  <result pre="Sendai virus, which is 15,384 nucleotides long, is like the" exact="Newcastle disease" post="virus except in having the PCV proteins and hemagglutinin"/>
  <result pre="virus, which is 15,384 nucleotides long, is like the Newcastle" exact="disease" post="virus except in having the PCV proteins and hemagglutinin"/>
  <result pre="(strains H7N1, H5N3, H1N1, H3N2) and paramyxoviruses (Sendai Virus, Newcastle" exact="Disease" post="Virus). Methods Cultivation and extraction of Actinomycetes To study"/>
  <result pre="of glucose (15 g), yeast extract (5 g), peptone (10 g) and the" exact="total" post="media volume of 1000 ml was adjusted to pH 7.2. To"/>
  <result pre="media. After 120 h of growth at 28 °C in a 100 ml" exact="total" post="growth culture, the broth from 3 separate flasks were"/>
  <result pre="biomass contained metabolites of extremophilic actinomycetes. Toxicity test of Actinomycetes" exact="Primary" post="toxicity analysis (hemolytic activity test) was first performed in"/>
  <result pre="H7N1, H5N3, H1N1, and H3N2) and paramyxoviruses (Sendai virus and" exact="Newcastle disease" post="virus). The action of actinomycetes extracts on the neuraminidase"/>
  <result pre="H5N3, H1N1, and H3N2) and paramyxoviruses (Sendai virus and Newcastle" exact="disease" post="virus). The action of actinomycetes extracts on the neuraminidase"/>
  <result pre="H7N1, H5N3, H1N1, and H3N2) and paramyxoviruses (Sendai virus and" exact="Newcastle disease" post="virus) on the model of chicken embryos was performed."/>
  <result pre="H5N3, H1N1, and H3N2) and paramyxoviruses (Sendai virus and Newcastle" exact="disease" post="virus) on the model of chicken embryos was performed."/>
  <result pre="of 10-days old chicken embryos for 24–72 h at 370С: Orthomyxoviruses:" exact="avian influenza" post="virus, strain A/tern/South Africa/1/61 (H5N3); human influenza virus, strain"/>
  <result pre="strain A/tern/South Africa/1/61 (H5N3); human influenza virus, strain А/Almaty/8/98 (H3N2);" exact="avian influenza" post="virus A/FPV/36/1 (H7N1), and human influenza virus, strain A/Vladivostok/2/09"/>
  <result pre="(pandemic variant, resistant to Tamiflu); Paramyxoviruses: avian paramyxovirus PMV-1/Beadette (Newcastle" exact="disease" post="virus), and Sendai virus, strain 960. Different doses of"/>
  <result pre="Viruses were grown for 24–72 h at 370С depending on the" exact="viral" post="strain. The presence of the viruses was indicated by"/>
  <result pre="test (HA-test). The ability of investigated preparations to inhibit virus" exact="infectious" post="activity was estimated by comparison of the results of"/>
  <result pre="of extract preparations (EIC50, mg/ml) capable of inhibiting 50% of" exact="viral" post="hemagglutination activity (HI50). The same calculation procedure was applied"/>
  <result pre="and Additional file 3: Figure S3. In these assays, the" exact="lower" post="concentrations of preparations to induce the measured effect indicated"/>
  <result pre="cells, or 10-days chicken embryos) for the toxicity tests. Overall," exact="lower" post="toxicity was observed when preparations were tested on the"/>
  <result pre="Overall, the CBS and CBN as growth conditions resulted in" exact="lower" post="toxicity of preparations since these samples required the highest"/>
  <result pre="in saline conditions, K-525-2S, had higher SI indexes against tested" exact="viral" post="strains than extracts from culture liquid or biomass extract"/>
  <result pre="liquid in neutral conditions Viruses Influenza virus H3N2 Influenza virus" exact="H1N1 Influenza" post="virus H5N3 Influenza virus H7N1 PMV-1/Beadette Sendai. strain 960"/>
  <result pre="inhibition concentration of preparation (EIC50, mg/ml) that inhibited 50% of" exact="viral" post="hemagglutination activity. We determined that most of the extremophiles"/>
  <result pre="inhibition (HI) of the H1N1 virus (Fig. 1a). Thus, the" exact="lower" post="the value for HI indicates better effectiveness of the"/>
  <result pre="Effective Inhibition Concentration (EIC50, mg/ml) of preparations against influenza virus" exact="type A." post="Actinomycetes extracts, K-192-1 N, K-192-2 N, K-192-2S, K-362-1S, K-362-2 N, K-525-2 N, K-525-2S"/>
  <result pre="strains grown in 2 N, 1S and 2S conditions both required" exact="lower" post="concentrations of preparations (and hence more active) to inhibit"/>
  <result pre="tested preparations (EC50, mg/ml) that caused 50% inhibition of virus" exact="infectious" post="activity was determined (Fig. 4a-f). Extracts of CBN and"/>
  <result pre="determined (Fig. 4a-f). Extracts of CBN and CBS preparations demonstrated" exact="lower" post="virus-inhibition activity against all investigated strains of influenza virus"/>
  <result pre="found to be most effective in inhibiting the Influenza A" exact="viral" post="subtype, PMV-1/Beadette and Sendai. strain 960, followed by the"/>
  <result pre="Viruses were grown for 24–72 h at 370С depending on the" exact="viral" post="strain. The presence of the viruses was indicated by"/>
  <result pre="test (HA-test). The ability of investigated preparations to inhibit virus" exact="infectious" post="activity was estimated by comparison of the results of"/>
  <result pre="extremophilic actinomycetes SI-index of actinomycetes preparations to determine the effective" exact="viral" post="inhibiting activity Further in experiments on chicken embryos, the"/>
  <result pre="to be more than 10 against all strains of influenza" exact="type A" post="viruses investigated. Additionally, both K-362-1S and K-362-2S had the"/>
  <result pre="available antiviral drugs, Rimantadine and Tamiflu. Also, the inhibition of" exact="viral" post="activity by studied extracts was comparable with plant antiviral"/>
  <result pre="than Tamiflu and Rimantadine against H3N2, H1N1, H5N3, and H7N1" exact="viral" post="strains Actinomycetes preparations required lower concentrations to effectively kill"/>
  <result pre="H3N2, H1N1, H5N3, and H7N1 viral strains Actinomycetes preparations required" exact="lower" post="concentrations to effectively kill 50% of viruses in comparison"/>
  <result pre="samples of the actinomycetes coming from CBN and CBS had" exact="lower" post="toxicity than other preparations against studied ortho- and paramyxoviruses."/>
  <result pre="different biological models used for toxicity hemolytic activity testing. The" exact="lower" post="toxicity was observed on the model of chicken embryos,"/>
  <result pre="activity testing. Overall, samples of actinomycetes culture broth possessed the" exact="lower" post="toxicity in comparison with the extracts of actinomycetes biomass."/>
  <result pre="far no study has reported antiviral activities against our tested" exact="viral" post="strains in extracts from actinomycetes strains grown in-vitro in"/>
  <result pre="of all actinomycetes strains except K-525, when investigated on influenza" exact="type A" post="and paramyxoviruses. However, the K-525 strain was the most"/>
  <result pre="further characterized to produce therapeutically effective antivirals for treatment of" exact="infections" post="caused by our tested viral strains. As previously mentioned,"/>
  <result pre="effective antivirals for treatment of infections caused by our tested" exact="viral" post="strains. As previously mentioned, several studies reported antiviral activities"/>
  <result pre="well established antivirals with the mechanism of antiviral actions on" exact="viral" post="replicative cycle and inhibiting the neuraminidase enzyme, respectively [29,"/>
  <result pre="virus surface which would prevent budding from the host cell," exact="viral" post="replication, and infectivity. Conclusions Overall, we found that the"/>
  <result pre="of compounds that can block the reproduction of influenza virus" exact="type A." post="Future studies will focus on isolation and characterization of"/>
  <result pre="followed by elucidation of the mechanism of action for the" exact="viral" post="inhibitory activities. Supplementary information LINK Additional file 1: Figure"/>
  <result pre="SongIn Vitro inhibitory activity of Alpinia katsumadai extracts against influenza" exact="virus infection" post="and hemagglutinationVirology Journal20107130710.1186/1743-422X-7-30721062499 4.PalesePeterInfluenza: old and new threatsNature Medicine200410S12S82S8710.1038/nm1141"/>
  <result pre="Vitro inhibitory activity of Alpinia katsumadai extracts against influenza virus" exact="infection" post="and hemagglutinationVirology Journal20107130710.1186/1743-422X-7-30721062499 4.PalesePeterInfluenza: old and new threatsNature Medicine200410S12S82S8710.1038/nm1141"/>
  <result pre="new threatsNature Medicine200410S12S82S8710.1038/nm1141 5.KilbourneEdwin D.Influenza Pandemics of the 20th CenturyEmerging" exact="Infectious" post="Diseases200612191410.3201/eid1201.05125416494710 6.MacLachlan NJ, Dubovi EJ,editors. Fenner’s Veterinary Virology (Fifth"/>
  <result pre="567–8. 10.1016/B978-0-12-800946-8.00017-9. 7.Brown VR, Bevins SN. A review of virulent" exact="Newcastle disease" post="viruses in the United States and the role of"/>
  <result pre="10.1016/B978-0-12-800946-8.00017-9. 7.Brown VR, Bevins SN. A review of virulent Newcastle" exact="disease" post="viruses in the United States and the role of"/>
  <result pre="the United States and the role of wild birds in" exact="viral" post="persistence and spread. Vet Res. 2017; 10.1186/s13567-017-0475-9. 8.DortmansJos CFMKochGuusRottierPeter"/>
  <result pre="Vet Res. 2017; 10.1186/s13567-017-0475-9. 8.DortmansJos CFMKochGuusRottierPeter JMPeetersBen PHVirulence of newcastle" exact="disease" post="virus: what is known so far?Veterinary Research201142112210.1186/1297-9716-42-12222195547 9.BousseTatianaChambersRaychel L.ScroggsRuth"/>
  <result pre="is known so far?Veterinary Research201142112210.1186/1297-9716-42-12222195547 9.BousseTatianaChambersRaychel L.ScroggsRuth AnnPortnerAllenTakimotoToruHuman parainfluenza virus" exact="type 1" post="but not Sendai virus replicates in human respiratory cells"/>
  <result pre="virus type 1 but not Sendai virus replicates in human" exact="respiratory" post="cells despite IFN treatmentVirus Research20061211233210.1016/j.virusres.2006.03.01216677733 10.TakahashiYōkoNakashimaTakujiActinomycetes, an Inexhaustible Source"/>
  <result pre="and Antiviral PropertiesPolish Journal of Microbiology201867325927210.21307/pjm-2018-04830451442 12.ChibaHarumiInokoshiJunjiNakashimaHidekiŌmuraSatoshiTanakaHaruoActinohivin, a novel anti-human" exact="immunodeficiency" post="virus protein from an actinomycete, inhibits viral entry to"/>
  <result pre="a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits" exact="viral" post="entry to cells by binding high-mannose type sugar chains"/>
  <result pre="antiviral activities of an actinomycete (Streptomyces sp.) isolated from a" exact="Brazilian" post="tropical forest soilWorld Journal of Microbiology and Biotechnology200420322522910.1023/B:WIBI.0000023824.20673.2f 14.UYEDAMasaruMetabolites"/>
  <result pre="by Actinomycetes —Antiviral Antibiotics and Enzyme Inhibitors—YAKUGAKU ZASSHI2004124846947910.1248/yakushi.124.46915297717 15.LiFangfangChenDaiweiLuShengshengYangGuangZhangXiaolingChenZhaoFanShengWuShaohuaHeJianAnti-Influenza A" exact="Viral" post="Butenolide from Streptomyces sp. Smu03 Inhabiting the Intestine of"/>
  <result pre="P.BeardP. D.The Hemagglutination-Elution Pattern as a Marker in Characterizing Newcastle" exact="Disease" post="VirusAvian Diseases197014354210.2307/15886165466096 18.KlimovAlexanderBalishAmandaVeguillaVicSunHongSchifferJaradLuXiuhuaKatzJacqueline M.HancockKathyInfluenza Virus Titration, Antigenic Characterization, and"/>
  <result pre="18.KlimovAlexanderBalishAmandaVeguillaVicSunHongSchifferJaradLuXiuhuaKatzJacqueline M.HancockKathyInfluenza Virus Titration, Antigenic Characterization, and Serological Methods for" exact="Antibody" post="DetectionMethods in Molecular Biology2012Totowa, NJHumana Press2551 19.JongesMarcelLiuWai Mingvan der"/>
  <result pre="Virus Inactivation for Studies of Antigenicity and Phenotypic Neuraminidase Inhibitor" exact="Resistance" post="ProfilingJournal of Clinical Microbiology201048392894010.1128/JCM.02045-0920089763 20.Li AF, Wang WH, Xu"/>
  <result pre="Actinomycetes from Extreme Environments with Potential to Produce Novel Antibiotics." exact="Central" post="Asian Journal of Global Health. 2018; 10.5195/cajgh.2018.337. 26.Turmagambetova AS,"/>
 </snippets>
</snippetsTree>
